Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of EC-MPS in Kidney Transplant Recipients
NCT00239070Phase 3Completed
- Sponsor
- Novartis
- Start
- Apr 2003
- Primary completion
- May 2006
- Modality
- Small Molecules
01
Overview
Phase 3, open-label, single-arm trial of mycophenolate sodium in kidney transplant rejection, sponsored by Novartis. Primary endpoints: Patient Survival, Graft Survival and 3 more. Started Apr 2003; status: completed.
02
Drugs
mycophenolate sodium
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT00239070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00239070.